AusBiotech has welcomed 27 new member organisations in the first half of 2025, reinforcing the sector’s growth and momentum.
The organisation said the new members range from start-ups to multinationals, spanning biotechnology, medical technology, digital health, research, and advanced manufacturing, further strengthening its national member community of more than 3,000.
This expanding member community reflects the increasing recognition of life sciences as a critical driver of Australia’s economic resilience and health security.
AusBiotech Deputy CEO, Rosane Hyland, said, “Our members are actively shaping the future of health in Australia and around the world. We are delighted to welcome this diverse cohort into our network — and look forward to supporting their work. Having a membership community that continues to grow is something we are very proud of.”
The new members include:
- Adherium;
- AdvanCell;
- ARM Hub;
- Aurora Biosynthetics;
- AusHealth Hospital Research Fund;
- BioNTech Australia;
- BioOra;
- Bird & Bird;
- Breakthrough T1D (formerly JDRF);
- Celleo Biotech;
- Cicada Innovations;
- Eli Lilly Australia;
- Emball’iso;
- Enimera RegsPlus;
- Facio BioTherapies;
- Grey Wolf Therapeutics;
- Invetech;
- LabConnect Australia;
- Mark Wainwright Analytical Centre;
- Miltenyi Biotec Australia;
- New England Biolabs (Australia);
- Proclinical;
- Prove Clinical Laboratories;
- Pulse Economics Consulting;
- Sartorius Australia Pty Ltd;
- Vertex Pharmaceuticals (Australia); and,
- Zuellig Pharma SSG Austral.
To learn more about membership and how to get involved in Australia’s life sciences ecosystem, visit the organisation's website.